Report an error   

Submitted: 02 October 2014 Modified: 18 September 2017
HERDIN Record #: PCHRD14100200022919

Clinical experience with BIAsp 30: Results from the Philippine cohort of the global a1chieve study.

1Mary Anne Lim-Abrahan,
2Anand B. Jain,
3Susan Yu-Gan,
4Leorino M. Sobrepena,
5Veronica A. Racho
College of Medicine - University of the Philippines Manila,
Clinical, Medical, Quality and Regulatory Affairs - Novo Nordisk Pharma (Malaysia) Sdn. Bhd,
Metropolitan Medical Center, Manila,
Davao Doctors Hospital,
San Pedro Hospital, Davao City,
Davao Medical School Foundation


OBJECTIVE: To evaluate the safety, effectiveness and health-related quality of life (HRQoL) parameters of A1chieve study participants in the Philippine cohort, who were treated with BIAsp 30.
METHODOLOGY: A1chieve is a non-interventional, six-month, observational study of 66,726 people with type 2 diabetes mellitus (T2DM), including both insulin users and non-insulin users, started on insulin detemir, insulin aspart, or BIAsp 30 in 28 countries across four continents. The present study evaluates the safety, effectiveness and HRQoL in 1,252 subjects from the Philippine cohort of the A1chieve study who were treated with BIAsp 30.
RESULTS: At baseline, the mean age, duration of diabetes and mean BMI were found to be 55.5±11.7 years, 7.2 ± 5.6 years and 25.4 ± 5.3 kg/m2, respectively. Seventy-eight percent (78%) of subjects were insulin naïve and 22% were prior insulin users. At baseline, glycemic control was poor (HbA1c = 9.9%) in the entire cohort. Overall there was a 2.7% reduction in mean HbA1c and 44.2% subjects achieved the HbA1c target of <7.0%, after 24 weeks of therapy with BIAsp 30. There were significant reductions in total cholesterol, LDL-cholesterol, triglycerides and systolic blood pressure after 24 weeks of therapy with BIAsp 30. There was no increase in the incidence of hypoglycemia among insulin-naïve subjects, while there was a marked reduction in hypoglycemia (4.93 to 2.53 events/person-year) among prior insulin users at 24 weeks.
CONCLUSION: BIAsp 30 is safe and efficacious for initiating and intensifying insulin therapy for Filipino T2DM patients.

Publication Type:
Publication Sub Type:
Clinical trials/Clinical investigations (RCT
Philippine Journal of Internal Medicine
Publication Date:
July-September 2014
Philippine College of Physicians

LocationCall NumberAvailable FormatAvailability
Philippine Journal of Internal Medicine Fulltext External Link (View)
Philippine Council for Health Research and Development Library Fulltext pdf (Request Document)